Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2023-12-05 Director's Dealing
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-12-05 English
FORM 4 SUBMISSION
Director's Dealing
2023-12-05 English
SC TO-I/A Filing
Capital/Financing Update Classification · 95% confidence The document is a Schedule TO/A (Amendment No. 3) filed with the SEC under Rule 13e-4, which relates to a tender offer statement. It details the final results of an issuer tender offer to exchange employee stock options for restricted stock units. The document includes specific transaction terms, participation numbers, and share counts. It is an amendment to a tender offer statement, not a full financial report or earnings release. The content focuses on capital structure changes via a tender offer exchange, which fits the Capital/Financing Update category. The document length is about 4875 characters, and it contains substantive transaction details rather than just an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-12-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 1, 2023. It announces a press release about clinical data presentations at a medical conference (American Epilepsy Society’s 2023 Annual Meeting). The document explicitly states it is furnishing information under Item 7.01 Regulation FD and includes a press release as an exhibit. There is no substantive financial data or detailed financial reporting, only an announcement of a press release. The document length is 3485 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories like earnings release or annual report.
2023-12-01 English
Merger & Acquisition 2023
Merger & Acquisition Classification · 95% confidence The document is a letter from counsel to the SEC responding to comments on an Amendment No. 2 to a Schedule TO filed by Stoke Therapeutics, Inc. Schedule TO filings relate to tender offer statements, which are part of takeover or exchange offer activities. The letter discusses revisions to the Exchange Offer disclosure and compliance with SEC rules. There is no financial data or report content here, only correspondence about a tender offer filing. This is not a full report, earnings release, or proxy statement, but a regulatory correspondence related to a tender offer. The Schedule TO and amendments are part of merger and acquisition activity filings. Therefore, the document is best classified under Merger & Acquisition (MA). The document length and detail confirm it is not a brief announcement or certification, but a substantive regulatory filing letter related to a tender offer amendment.
2023-11-17 English
SC TO-I/A Filing
M&A Activity Classification · 95% confidence The document is a Schedule TO/A (Amendment No. 2) filed with the SEC under Rule 13e-4, which relates to a tender offer by Stoke Therapeutics, Inc. It amends and supplements a previously filed Schedule TO regarding an exchange offer for employee stock options. The document includes detailed terms of the exchange offer, conditions, procedures, and references to financial information incorporated by reference from the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The primary purpose is to update and amend the tender offer statement, not to present a full financial report or earnings release. This type of filing is specifically related to a tender offer transaction and is best classified under M&A Activity (TAR) as it concerns a takeover bid or merger-related tender offer statement. The document is substantive and not merely an announcement or certification, so it is not RNS or RPA. Therefore, the correct classification is TAR with high confidence.
2023-11-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.